Team NIB

Biologic therapies have transformed retinal disease management, but the burden of frequent intraocular injections remains a significant barrier to patient adherence and comfort. Efforts to increase the half-life of intraocular biologics were mostly unsuccessful since they resulted in reduced retinal penetration and low efficacy. Hence, there is an urgent need for a fundamentally novel biologics design principle, enabling long-term intraocular activity and at the same time deep retinal penetration. Team NIB aims to develop an innovative human organotypic in vitro platform technology for the validation of next-generation intraocular biologics. Selected therapeutics target deep within the retina while substantially extending the time between intraocular injections.